However, a recent study demonstrated that the phosphatase activity of PP2A is suppressed in chronic myeloid leukemia and other malignancies characterized by aberrant oncogenic kinase activity, and preclinical studies show that the pharmacological restoration of PP2A tumor-suppressor activity by PP2A-activating drugs (e.g., FTY720) effectively antagonizes cancer development and progression [30]. This evidence concerns the gene PTPA and neoplasm.